Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Intra-tumor Double ICIs in NSCLC
NCT06492421Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jul 2024
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab, pembrolizumab and durvalumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Pathologic Complete Response Rate at 6 months and Major Pathologic Response Rate at 6 months. Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06492421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492421.